...

Funding News

by user

on
1

views

Report

Comments

Transcript

Funding News
Funding News
June 11, 2007
NEWS & NOTICES FOR THE WEEK ENDING JUNE 8, 2007
NCRR/NIH Roadmap to Publish a Limited Solicitation for Pilot Projects in Informatics for
Clinical and Translational Science Awards (CTSAs) [NOT-RR-07-012] (6/8) The overarching
purpose of the CTSA program is to provide an institutional home for the evolving new discipline of
clinical and translational science. The objective of the solicitation will be to advance development,
adoption, implementation, and dissemination broadly of tools, standards, and practices for
information exchange to facilitate the performance of research by clinical investigators and their
collaborators within, among, and beyond CTSAs. The FOA will be published in the fall. The award
will be in the form of a contract ranging from $500K to $1M a year over 2 years. Two awards are
expected to be made.
LCRC Annual Report Due
Dr. Ochoa requests that members of the Cancer Center please provide the Grants and Development
Office with the following lists:
• Honors/recognitions, committee appointments, and new collaborations since January 1 (July 1,
2006, if you did not provide this information for the semi-annual report in December).
• Peer-reviewed publications and invited presentations since January 1 (or July 1...). Please
indicate which, if any, publications are co-authored by Tulane researchers.
• Active grants/contracts. This information should include the agency name, award number, dates of
award, annual direct and total costs, project title, and your role on the project (if not PI). This list
should not include grants in no-cost extensions.
If you would like information about LCRC funding opportunities, please contact us at 568-3494.
Correct email Address for Dr. Tiskus
When preparing applications, please use [email protected] as the contact address for Dr. Tiskus.
New Grants and Development Office
Jonna Ellis and I are now located in 409B of the CSRB building. My number is 568-3494; Jonna’s is
x5144.
NIH & CDC SOLICITATIONS
NCI/NCAAM Omics and Variable Responses to CAM: Secondary Analysis of CAM Clinical
Trials – R01, R21[PAR-07-377], [PAR-07-378] (6/6)
Opens
July 14
Receipt dates
September 14, 2007-2009
Closes
September 15, 2009
Intended to leverage NCCAM’s and NIH’s investment in ongoing and completed clinical trials,
this initiative encourages examination of differences in genomics, proteomics, and metabolomics
and other omics that may be responsible for variations in individual responses to complementary
and alternative medicine (CAM) (NCCAM) or bioactive food component (NCI) interventions using
samples obtained from ongoing and completed clinical studies.
Restrictions
Competitive renewals may not be awarded.
NIH/OBSSR/NCCAM/NEI/NHLBI/NIAMS/NIAID/NICHD/NIDCR/NIDDK/NIEHS/NIGMS/NIMH/NINDS
/NINR/NIA/NIAAA/NICHD/NIDA/NILM/OPHR/(CDC) Behavioral and Social Science Research on
Understanding and Reducing Health Disparities – R01, R21 [PAR-07-379][PAR-07-380] (6/7)
Opens
July 19, 2007
LOI Due
August 20, 2007-9
Receipt date
September 19, 2007-8; September 18, 2009
Closes
September 19, 2009
Encourages behavioral and social science research on the causes and solutions to health and
disabilities disparities in the US population. Health disparities between, on the one hand,
racial/ethnic populations, lower socioeconomic classes, and rural residents and, on the other
hand, the overall US population are major public health concerns. Emphasis is placed on
research in and among three broad areas of action: (1) Public policy, (2) health care, and (3)
disease/disability prevention. Particular attention is given to reducing health gaps among groups.
Proposals that utilize an interdisciplinary approach, investigate multiple levels of analysis,
incorporate a life-course perspective, and/or employ innovative methods such as system science
or community-based participatory research are particularly encouraged.
Commitment
20-30 R01 awards and 10-20 R21 awards in Year 1
NIGMS Research on Interventions that Promote Research Careers – R01 [RFA-GM-08-005] (6/5)
Opens
September 24, 2007
LOI Due
September 24, 2007
Receipt date
October 22, 2007
Closes
October 23, 2007
Supports research to test assumptions regarding existing or potential interventions that are
intended to increase the preparedness for careers in biomedical and behavioral research, with a
particular interest in those interventions specifically designed to increase the number of
underrepresented minority students entering careers in biomedical and behavioral research. The
proposed research need not be restricted to underrepresented minority students. Â Comparative
research which analyses the experience of all ethnicities in order to place that of
underrepresented students in context and to learn whether and how interventions should be
tailored to make more underrepresented students successful in biomedical careers may well be
particularly illuminating and is, therefore, encouraged.
Commitment
$2.4M for 6-8 awards
NIDCR Osteoimmunology- Crosstalk between Immune System and Bone – R01, R21
[RFA-DE-08-006], [RFA-DE-08-007] (6/7)
Open Date:
Receipt Date:
Close Date:
May 31, 2007
July 9, 2007
July 10, 2007
Solicits novel research projects designed to provide a fundamental understanding of the
intersystem crosstalk between alveolar bone and the immune system, and how osteoimmunology
operates in normal and pathologic conditions. It will contribute to our understanding of how both
systems are physiologically regulated, at the molecular and cellular levels and at the level of
organ systems. Specifically this initiative solicits research that will identify the influence of the
immune system on oral bone biology; the extent to which normal immune responses affect oral
bone homeostasis; the consequences of oral bone metabolism on adaptive immune responses;
the interplay between the immune system and age-related oral bone changes; and the changes in
the host immune system that impact oral bone loss. The emerging field of osteoimmunology is
important for formulating intervention strategies for periodontitis as well as for basic and clinical
studies in related fields.
Examples of Knowledge Gaps
•
•
•
•
•
•
•
•
•
•
The immunopathological mechanism(s) that link periodontal and dental pulp infection and
pathological bone resorption.
The role of innate and adaptive immune cells in normal and pathological bone turnover in the
oral cavity.
The role of cytokines and other cellular factors in oral bone development and pathology.
The role of cells/factors that regulate B cells and how B cells regulate osteoblasts and
osteoclasts in the oral cavity.
The roles of circulating lymphocytes and other immune cells in normal and pathological oral
bone metabolism.
Identification of new therapeutic strategies to prevent inflammation-induced bone loss.
Definition of regulatory signals and pathways that influence both oral bone and immune cells,
such as signals between immune cells and neural cells.
Immunomodulatory strategies to reduce or prevent oral bone loss.
Whether osteo-immune cross-talk is different in oral vs axial/appendicular bone.
Ontogeny of osteoimmune interactions in the host.
Commitment
$2M for R01s and $1M for R21s in FY08
NCI Development, Application, and Evaluation of Prediction Models for Cancer Risk and
Prognosis – R01 [PA-07-021],[ PA-07-022] (11/20/06)
Opens
Receipt Dates
Closes
January 5, 2007
October 5, January 5, June 5 (standard R01)
October 16, January 16, June 16 (standard R21)
January 3, 2010
Encourages clinicians, epidemiologists, geneticists, statisticians, and translational researchers
working in the field of cancer control and prevention to improve existing models for cancer risk
and prognosis. Specifically, this program is designed to stimulate efforts towards: (1) the development
of comprehensive models of risk, prognosis, and response to therapy, (2) integrating diverse types of
data in these areas, (3) validating such models, and (4) evaluating the utility of integrated models in
research and clinical settings.
Restriction
•
Doesn’t fund research on developing/characterizing biomarkers
NIH Exploratory Studies in Cancer Detection, Diagnosis, and Prognosis – R21 [PA-06-299]
(3/30/06)
May 2, 2006
Opens
October 16, January 16, June 16 (standard)
Receipt Dates
November 2, 2008
Closes
Intended to support translational studies which identify promising new means for cancer detection
and diagnosis and which provide the initial, critical information necessary to decide whether
potential clinical utility justifies further investment. Applicants should explain the significance of
the proposed research in terms of its potential for clinical application. Priority will be given to welldesigned studies that will help us to differentiate those new markers and techniques that have
potential clinical utility from those that do not.
This funding opportunity announcement is sponsored jointly by the Cancer Diagnosis Program
and the Cancer Therapy Evaluation Program (Division of Cancer Diagnosis and Treatment) and
the Cancer Biomarkers Research Group (Division of Cancer Prevention) of the National Cancer
Institute.
NCI Prioritizing Molecular Targets for Cancer Prevention with Nutritional Combinations – R01
[PA-07-100] (12/1/06)
January 5, 2007
Opens
October 5, January 5, June 5 (standard)
Receipt Dates
Closes
November 2, 2009
Solicits innovative research applications to enhance mechanistic understanding of the dynamic
interrelationship between bioactive food components and/or food combinations and cancer prevention.
Projects proposed in response to this FOA must focus on either multiple dietary bioactive components,
intact foods, and/or multiple foods utilizing physiologically relevant concentrations of the bioactive
agents. The objective is to investigate the impact of dietary components on complex cellular and
molecular networks to better understand the basis for the multifaceted interactions of food components
in cancer prevention. Proposed projects should apply new high-throughput genomic, epigenomic,
proteomic, and metabolomic technologies to either evaluate multiple molecular targets within a cancer
process or multiple processes. The main outcome of these studies must be the prioritization of
targets/processes that are most relevant to cancer prevention by dietary components. The overall longterm goal is to use such information in developing dietary strategies to reduce cancer risk and/or
modify tumor behavior.
See also NCI Exploratory Cancer Prevention Studies Involving Molecular Targets for Bioactive
Food Components – R21 [PA-07-362], summarized in Funding News 15
Additional Opportunities
• NIAID International Research in Infectious Diseases (IRID) Program – R01 [PAR-07-376]
(6/8)
PRIVATE GRANTS
Parker B. Francis Fellowship in Pulmonary Research
Receipt Date
Starts
October 1
July 1
Intended to provide assured support, during their earlier years, for junior members of the faculty as
they establish their laboratories. It is hoped that the assurance provided through the Program will
encourage successful applicants to be more venturesome in their research and future applications
for support than would otherwise be likely. The ideal candidate is in transition between postdoctoral
training and a career as an independent investigator.
A broad array of approaches to lung biology and respiratory medicine, ranging from cell and
molecular studies, to those involving epidemiologic and clinical aspects of human subjects are
appropriate. We also encourage applications from pulmonary medicine specialists interested in
pursuing research in bioethical aspects of pulmonary medicine or critical care. Potential topics
include, but are not limited to, the ethics of clinical trials in critical care, end-of-life decisions and
resource allocation. The context of all these topics should be pulmonary biology and lung disease.
Solicitation
Program press release
Scientific Advisory Board
Award
Commitment
Restrictions
$48-50K/year for 3 years
• No more than 7 years research experience
• At least 2-3 co/publications (1-2 accepted on rare occasions)
• Citizen/perm resident of N. American country—or can demonstrate the steps
have been taken towards permanent residenty
•
•
•
•
•
•
≥75% effort towards research project
No NIH K o r R01 grants
Any NIH/MRC training grants must be relinquished at time of award
Mentor required
Only 2 active awards per department
No indirect costs.
Leukemia and Lymphoma Society Career Development Program
Pre-app
Receipt Date
September 17,2008
October 1,2008
Supports fundamental research in genetics, molecular and cell biology, molecular pharmacology,
molecular virology and immunology. The program also encompasses translational research directly
relevant to the improved treatment or diagnosis of leukemia, lymphoma, myeloma and, where
applicable, to prevention.
CDP Reviewers List (January 8-10, 2007 review)
Scholars
$105K/year for 5
years (+5K
indirects)
• Indep faculty
pos. or equiv.
• Substantial
funding record
Additional
Scholars in
Clinical
Research
$105K/year for 5
years (+5K
indirects)
• Conducting
applied resh.
often involving
early-phase
clinical trials
• Indep faculty
pos. or equiv.
• Concomitant
support for rsh.
Special Fellow
$60.K/year for 3
years (+4.5K
indirects)
• ≥2 years
postdoctoral
experience
• Sponsor
Special Clinical
Research Fellow
$60.K/year for 3
years (+4.5K
indirects)
• MD/Phd or
equiv. w/ 2
years clinical
hematology,
oncology,
hematology/on
cology, or
hematopatholo
gy training or
postdoctoral
research
training in a
clinical
discipline (e.g.,
cytogenetics,
molecular
pathology)
• Evidence that
career focus
will be on
prevention,
diagnosis, or
treatment of
leukemia,
lymphoma, or
myeloma
Annual renewals on a non-competitive basis
Fellow
$51.7K/year for
5 years (+3.3K
indirects)
• ≤ 2 yrs
postdoctoral
exp.
• Sponsor
• Substantial
funding record
American Gastrological Association (AGA) Funderburg Research Scholar Award
Receipt Date
September 5
Awarded to an established investigator working on novel approaches in gastric cancer, including the
fields of gastric mucosal regeneration and regulation of cell growth (not as they relate to peptic ulcer
disease inflammation (including Helicobacter pylori) as precancerous lesions; genetics of gastric
oncogenes in gastric epithelial malignancies; epidemiology of gastric cancer; etiology of
malignancies; or clinical research in the diagnosis or treatment of gastric carcinoma.
Award
Commitment
Requirements
Application
$25K/year for 2 years
One (1) award per year
• Must hold faculty positions at North American
• Established researcher in gastrology
• AGA member
Via email
American Gastrological Association (AGA) Research Scholar Awards
Receipt Date
Start Date
September 5
July 1
Enables young investigators to develop independent and productive research careers in
gasterentrology, heptology and related areas by ensuring that a major proportion of their time is
protected for research.
Recipients will be selected based on novelty, feasibility, and significance of the proposal; attributes of
the candidate, including potential for independence; evidence of institutional commitment; and the
research environment. Candidate should state clearly how the additional training will benefit his/her
research career.
Criteria.pdf
Application.doc
Award
Commitment
Restrictions
Review
Application
$75K a year for 3 years
Six (6) awards
• Ph, MD or equiv
• Within 5 years of postdoc/clinical training
• Members of AGA
• Full-time faculty appointment at North American university
• Cannot hold/have held an R01, R29, R21, K award, VA Career Development
Award, or nonfederal award with similar objectives ( American Liver
Foundation, Crohn’s and Colitis Foundation of America, Robert Wood
Johnson Foundation or Glaxo Institute of Digestive Health).
• Must devote 70% research effort to gastrointestinal tract or liver.
• If an extraumural award of equal or greater amount is received during period
of this award, 75% must be relinquished. If another award is received prior to
this award, one must be relinquished.
• If applicant has project incorporated into a senior investigator’s federal grant,
that project must be cleary delineated from the proposed research.
Review committee of AGA members
Via email
American Gastrological Association (AGA) Bridging Grants
June 14, October, 14, February 14
Receipt Dates:
Assists investigators were not awarded their first R01 or the first renewal of their R01 to continue
their gastroenterology related research. Two awards will be made following each of the three annual
NIH review cycles and availability of Summary Statements.
Award
Commitment
Restrictions
$50K for 1 year
6 awards per year
• For investigators applying for their first R01 or second R01 either as a
competitive renewal or a new R01 (includes investigators going from a K
award to their first R01).
• Cannot receive over $75K in extramural funding
• MD, PhD or equiv
• Faculty appointment at university/research institution
• NIH proposal must have been approved and not funded or have received
high commendation but was not funded.
American Cancer Society (ACS) Various Programs
Receipt Date
October 15
The following programs are summarized in Funding News 3S:
•
•
•
•
•
•
•
ACS Mentored Research Scholar Grant in Applied and Clinical Research (April 1, too)
Cancer Control Career Development Awards for Primary Care Physicians
Postdoctoral Fellowships (April 1, too)
Doctoral Training Grants in Oncology Social Work
Master's Training Grants in Clinical Oncology Social Work
Physician Training Awards in Preventive Medicine
Doctoral Degree Scholarships in Cancer Nursing
The ACS Mentored Research Scholar Grant in Applied and Clinical Research is summarized
in Funding News 2S. (Applications also accepted April 1.)
APPROACHING DEADLINES
The following programs have been summarized in previous issues of Funding News, which are available on
the Cancer Center website under Research/Grants/Summary Information. (Red indicates that an LOI or preapplication was required prior to the application date.)
Due Date
Program
More Info
Issue #
June 12
DOD BCRP Idea Award
W81XWH-07BCRP-IDEA
11
June 12
DOD BCRP Impact Award
W81XWH-07BCRP-IMPT
11
June 12
NIH NHLBI Career Transition Award – K23
PAR-07-317
June 16
Standard R03 and R21 applications due
June 16
Thrasher Research Fund (clinical/translational pediatric
research)
June 19
NHLBI Short-Term Research Education Program to Increase
15
RFA-HL-07-013
12
– LOI
Diversity in Health-Related Research – R25
June 20
NCI/NEI/NHLBI/NHGRI/NIA/NIAAA/NIAMS/NIBIB/NICHD/NIC
CR/NIDA/NIEHS/NIGMS/NIMH/NINDS/NINR Nanoscience and
Nonotechnology in Biology and Medicine – R01, R21
PAR-07-033
PAR-07-034
2
June 25
NIH NIAID HIV Interdisciplinary Network for Pathogenesis
Research in Women – U19
RFA-AI-07-009
8
June 25
NIAID HIV Interdisciplinary Network for Pathogenesis Research
in Women – U19
RFA-AI-07-009
7
June 26
NIAID Novel HIV Therapies: Integrated Preclinical/Clinical
Program (IPCP) – U19
RFA-AI-07-019
10
June 26
AACR Funding Opportunity for Metastatic Colon Cancer
Research
15
June 27
AACR Jeannik M. Littlefield- Grants in Metastatic Colon
Cancer Research
18
June 28
NIH Roadmap National Institutes of Health Rapid Access to
Interventional Development (NIH-RAID Pilot) – X01
PAR-07-358
14
June 29
NIAID B Cell Immunology for Protective HIV-1 Vaccines – U01,
R21
RFA-AI-07-014
RFA-AI-07-015
10
June 29
NIH NIEHS/NHGRI Human Genes and the Environment
Research Training Program/NRSA Institutional Training Grants –
T32
RFA-ES-07-002
5
July 2
American Institute for Cancer Research (AICR) Investigator
Initiated Grant (IIG) and Post-Doctoral Grant Award (PDA)
July 10
NCRR National Gene Vector Biorepository and Coordinating
Center – P40
RFA-RR-07-002
10
July 9
Quick Trial Grants For Novel Cancer Therapies: Exploratory
Research – R21
PAR-06-45
1
July 12
Ellison Medical Foundation (EMF) Senior Scholar Award in
Aging
July 12
NSF Biomolecular Systems Cluster,
Cellular Systems Cluster, and Genes and Genome Systems
Cluster
PD 04-1144
PD 04-1114
PD 04-1112
1
July 13 –
LOI
FIC/NCI/NIAAA/NIAID/NIDCR/NIDA/NINH/NINR/ORWH AIDS
International Training and Research Program – D43
PAR-07-239
12
July 14 –
LOI
NIDCR Oral Mucosal Vaccination against HIV Infection – R01,
R21
RFA-DE-08-003
RFA-DE-08-004
12
July 17
Competitive Continuation of Centers of Biomedical Research
Excellence (COBRE) – P20
RFA-RR-07-001
11
14
2
July 19
NHLBI Short-Term Research Education Program to Increase
Diversity in Health-Related Research – R25
RFA-HL-07-013
12
July 20
NIDA/NIEHS Mechanism for Time-Sensitive Research
Opportunities – R21 (LOI due 1 month prior)
PAR-07-345
11
July 23
Cancer Treatment Research Foundation
July 29 –
LOI
NIH NIGMS Molecular Probes for Microscopy of Cells – R01
August 1
Melanoma Research Foundation – Established Investigator
Award; Career Development Award
August 3
NIH NCCAM Ruth L. Kirshstein NSRA for Postdoctoral Training
in Complementary and Alternative Medicine – F32
PAR-07-319
6
August 4
– LOI
NIHM National Neuro AIDS Tissue Consortium (NNTC) Data
Coordinating Center (DCC) -– U01
RFA-MH-08-020
17
August
14
FIC/NCI/NIAAA/NIAID/NIDCR/NIDA/NINH/NINR/ORWH AIDS
International Training and Research Program – D43
PAR-07-239
12
August
14
NIDCR Oral Mucosal Vaccination against HIV Infection – R01,
R21
RFA-DE-08-003
RFA-DE-08-004
12
August
14 – LOI
NIH Roadmap National Institutes of Health Rapid Access to
Interventional Development (NIH-RAID Pilot) – X01
PAR-07-358
14
August
15
Burroughs Wellcome Fund (BWF) Clinical Scientists Awards in
Basic Research
August
20
NIDA/NIEHS Mechanism for Time-Sensitive Research
Opportunities – R21 (LOI due 1 month prior)
PAR-07-345
11
August
21 – LOI
Specialized Programs of Research Excellence (SPOREs) in
Human Cancer, 2007 – P50
PAR-06-505
1
August
21– LOI
NIH FIC/NCI/NIA/NIBIB/NIEHS/NINDS/ODS Global Research
Initiative Program, Basic/Biomedical Sciences – R01
PAR-07-239
10
August
25
Avon Foundation – Breast Cancer Prevention Research
Initiative
August
27 – LOI
NIH NCI Application of Emerging Technologies for Cancer
Research – R21, R33, SBIR(R43,R44), STTR(R41,42)
RFA-CA-07-035
RFA-CA-07-036
RFA-CA-07-041
RFA-CA-07-042
3
August
27 – LOI
NIH NCI Innovations In Cancer Sample Preparation –
SBIR(R43,R44), STTR(R41,42)
RFA-CA-07-043
RFA-CA-07-044
3
August
27 – LOI
NIH NCI Innovative Technologies for Molecular Analysis of
Cancer (IMAT) – R21, R33, SBIR(R43,R44), STTR(R41,42)
RFA-CA-07-033
RFA-CA-07-034
RFA-CA-07-039
RFA-CA-07-040
3, 16
August
29
NIH NIGMS Molecular Probes for Microscopy of Cells – R01
PAR-07-234
9
16
PAR-07-234
9
17
12
17
Sept TBA
Concern Foundation Conquer Cancer Now Award
18
Sept. 4
American Lung Association – Research Grants, Clinical
Research Grants, Career Investigators; Training Awards, and
Alliance Awards
17
Sept. 4
NIHM National NeuroADIS Tissue Consortium (NNTC) Data
Coordinating Center (DCC) – U01
RFA-MH-08-020
17
Sept. 7
NCI/NBIB/NEI/NHLBI/NHGRI/NIA/NIAMS/NICHD/NIDA/NIDCD/
NIDCR/NIEHS/NINDS Bioengineering Research Partnerships –
R01
PAR-07-352
12
Sept. 7
Standard AIDS-related applications due, including:
• NIDA AIDS-Science Track Award for Research Transition (ASTART) – R03
PAR-07-347
12
Sept. 14
Cancer Research and Prevention Foundation (CRPF) Grants
and Fellowship Program
Sept. 14
NIH Roadmap National Institutes of Health Rapid Access to
Interventional Development (NIH-RAID Pilot) – X01
Sept. 15
Cancer Research and Prevention Foundation CRPF Grants and
Fellowships Program
Sept. 20
NIH Framework Programs for Global Health - R25
RFA-TW-08-001
15
Sept. 20
NIDA/NIEHS Mechanism for Time-Sensitive Research
Opportunities – R21 (LOI due 1 month prior)
PAR-07-345
11
Sept. 21
NIH FIC/NCI/NIA/NIBIB/NIEHS/NINDS/ODS Global Research
Initiative Program, Basic/Biomedical Sciences – R01
PAR-07-239
10
Sept. 21
FIC/NCCAM/NIA/NIAAA/NIBIB/NIDCD/NIDCR/NIDA/NIEHS/NIN
DS International Research Collaboration – Basic Biomedical
(FIRCA-BB) – R03
PAR-07-335
10
Sept. 25
NIH NCI Cancer Education and Career Development Program –
R25
PAR-06-511
3
Sept. 27
NIH NCI Application of Emerging Technologies for Cancer
Research – R21, R33
RFA-CA-07-035
RFA-CA-07-036
3
Sept. 27
NIH NCI Innovative Technologies for Molecular Analysis of
Cancer (IMAT) – R21, R33, SBIR(R43,R44), STTR(R41,42)
RFA-CA-07-033
RFA-CA-07-034
3, 16
Sept. 28
NIH NCI Innovative Technologies for Molecular Analysis of
Cancer (IMAT) –SBIR(R43,R44), STTR(R41,42)
RFA-CA-07-039
RFA-CA-07-040
3, 16
Sept. 28
NIH NCI Application of Emerging Technologies for Cancer
Research –SBIR(R43,R44), STTR(R41,42)
RFA-CA-07-041
RFA-CA-07-042
3
Sept. 28
NIH NCI Innovations In Cancer Sample Preparation –
SBIR(R43,R44), STTR(R41,42)
RFA-CA-07-043
RFA-CA-07-044
3
Sept. 28
– LOI
NHLBI Summer Institute Program to Increase Diversity in HealthRelated Research (SIPID) – R25
RFA-HL-07-012
17
12
PAR-07-358
14
4
Oct. 1
Charlotte Geyer Foundation
13
Oct. 1
Wendy Will Case Cancer Fund
14
Oct. 1
Burroughs Wellcome Fund – Biomedical Scientists
18
Oct. 1
NCI Clinical Correlative Studies: Exploratory Studies in Cancer
Detection, Diagnosis and Prognosis – R21
Oct. 5
Standard R01 applications due
Oct. 8
Cancer Treatment Research Foundation
Oct. 12
Standard Career Development (K) applications due, including:
• NHLBI/NIDDK/NIAAA/NIEHS Career Enhancement Award for
Stem Cell Research – K18
•
NIH Pathway to Independence (PI) Award (K99/R00)
PA-05-165
15
16
PAR-07-358
PA-07-297
14
18
Oct. 15
American Cancer Society (ACS)
• Cancer Control Career Development Awards for Primary Care
Physicians
• Postdoctoral Fellowships
• Doctoral Training Grants in Oncology Social Work
• Master's Training Grants in Clinical Oncology Social Work
• Physician Training Awards in Preventive Medicine
• Doctoral Degree Scholarships in Cancer Nursing
3S
Oct. 15
ACS Mentored Research Scholar Grant in Applied and Clinical
Research
2S
Oct. 15
NCI-Avon “Progress for Patients” (PFP) Awards for Early Phase
Clinical Interventions and Biomarkers in Breast Cancer (Limited
Competitive Supplements [Revisions] for P30 Cancer Center
Support Grants)
PAR-07-244
10
Oct. 15 –
LOI
Oct. 16
NIH Centers for Research to Reduce Disparities in Oral Health –
U54 (Cooperative Agreement)
Standard R03, R21, R33, R34, and R36 applications due
RFA-DE-08-008
15
Oct. 19 –
LOI
Thrasher Research Fund (clinical/translational pediatric
research)
Oct. 20
NIDA/NIEHS Mechanism for Time-Sensitive Research
Opportunities – R21 (LOI due 1 month prior)
PAR-07-345
11
Oct. 23
NIGMS/NIEHS Collaborative Studies on Systems Biology of
Complex Phenotypes – R01
PAR-07-358
14
Oct. 29
NHLBI Summer Institute Program to Increase Diversity in HealthRelated Research (SIPID) – R25
RFA-HL-07-012
17
Nov. 15
NCI-Avon “Progress for Patients” (PFP) Awards for Early Phase
Clinical Interventions and Biomarkers in Breast Cancer (Limited
Competitive Supplements [Revisions] for P30 Cancer Center
Support Grants)
PAR-07-244
10
Nov. 15
NIH Centers for Research to Reduce Disparities in Oral Health –
U54 (Cooperative Agreement)
NIDA/NIEHS Mechanism for Time-Sensitive Research
Opportunities – R21 (LOI due 1 month prior)
RFA-DE-08-008
15
PAR-07-345
11
Nov. 19
15
Nov. 20
Thrasher Research Fund (clinical/translational pediatric
research) (LOI due June 16)
15
Dec. 1 –
LOI
Gerber Foundation Grants
15
Dec. 5
Kimmel Foundation Translational Science Award
2S
Dec.8
NIH NCCAM Ruth L. Kirshstein NSRA for Postdoctoral Training
in Complementary and Alternative Medicine – F32
Dec. 14
American Institute for Cancer Research (AICR) Investigator
Initiated Grant (IIG) and Post-Doctoral Grant Award (PDA)
Dec. 15
NIH Roadmap National Institutes of Health Rapid Access to
Interventional Development (NIH-RAID Pilot) – X01
PAR-07-358
14
Dec. 20
NIDA/NIEHS Mechanism for Time-Sensitive Research
Opportunities – R21 (LOI due 1 month prior)
PAR-07-345
11
PAR-07-319
6
14
GENERAL INFORMATION○
Unless otherwise specified, for each program description summarized in Funding
News, the following guidelines apply:
•
•
•
•
•
•
•
•
•
•
•
Dollar amounts represent direct costs.
NIH R01 awards are for unspecified amounts that are dependant on
available funding and the nature of applications received; they are
renewable.
NIH R03 awards are up to of $200K over two years and are nonrenewable.
NIH R21 awards are up to $275K over two years and are nonrenewable.
NIH AIDS-related proposals are associated with the standard receipt dates
May 7, September 7 and January 7.
Applicants/Institutions can submit more than one application.
All applicants with the skills, knowledge and resources necessary to
perform proposed research are eligible.
No institutional restrictions other than the general NIH standards apply.
Not every NIH Institute and Centers supports all types of funding
mechanisms. For example, when co-sponsoring an initiative, NEIHS may
offer both R01 and R03 award mechanisms, whereas NIE will offer only the
former.
For programs with multiple participating Institutes, the sponsoring Institute
is underlined.
In the table of Approaching Deadlines, dates in red indicate that a preapplication or LOI was due.
No. 19, June 4, 2007
Jonna Ellis
&
Heidi Davis, Editor
Office of Grants and Development
[email protected]
Fly UP